ALOPECIA AREATA
Clinical trials for ALOPECIA AREATA explained in plain language.
Never miss a new study
Get alerted when new ALOPECIA AREATA trials appear
Sign up with your email to follow new studies for ALOPECIA AREATA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Sun-Powered clothing could ease psoriasis and hair loss
Disease control CompletedThis study tested special clothing made with Lumiton yarn that captures sunlight and turns it into red and near-infrared light, aiming to improve skin conditions like psoriasis, alopecia areata, and polymorphous light eruption. Eighteen adults with mild-to-severe forms of these c…
Matched conditions: ALOPECIA AREATA
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Hair loss drug shows promise in major trial
Disease control CompletedThis study tested baricitinib, an anti-inflammatory pill, in 784 adults with severe or very severe alopecia areata, a condition causing extensive hair loss. Participants received either baricitinib or a placebo for up to 52 weeks. The main goal was to see if baricitinib could reg…
Matched conditions: ALOPECIA AREATA
Phase: PHASE2, PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hair loss drug shows promise in large global trial
Disease control CompletedThis study tested a drug called PF-06651600 in over 1,000 adults and teenagers with alopecia areata, a condition that causes patchy or complete hair loss. The goal was to see if the drug is safe and helps hair grow back over the long term. A smaller group also checked how well th…
Matched conditions: ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New pill shows promise for regrowing hair in severe alopecia
Disease control CompletedThis study tested the drug baricitinib in 606 adults with severe or very severe alopecia areata, a condition causing significant hair loss. Participants took either baricitinib or a placebo pill daily for up to 36 weeks. The main goal was to see if baricitinib could regrow enough…
Matched conditions: ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a Low-Dose immune therapy restore hair in severe alopecia?
Disease control CompletedThis Phase 3 trial tested whether low doses of interleukin-2 (IL2) can help people with severe alopecia areata, a condition causing patchy or total hair loss. 44 adults with at least 50% scalp hair loss who had not responded to other treatments received either IL2 injections or a…
Matched conditions: ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a common arthritis drug ease skin woes in down syndrome?
Disease control CompletedThis study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers chec…
Matched conditions: ALOPECIA AREATA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Hair loss drug shows promise in Long-Term trial
Disease control CompletedThis study tested the long-term safety and effectiveness of a drug called CTP-543 in 407 adults with moderate to severe alopecia areata, a condition that causes patchy or complete hair loss. Participants had already completed 24 weeks of treatment in a previous trial. The goal wa…
Matched conditions: ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Sun Pharmaceutical Industries, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Pill vs. needle: can roflumilast regrow hair in alopecia areata?
Disease control CompletedThis completed trial tested whether an oral anti-inflammatory drug called roflumilast can regrow hair as well as steroid injections in people with mild-to-moderate patchy alopecia areata. Fifty adults with limited to moderate hair loss were enrolled. The main goal was to measure …
Matched conditions: ALOPECIA AREATA
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 26, 2026 17:01 UTC
-
Small study reveals immune changes after hair loss drug
Knowledge-focused CompletedThis study looked at 20 adults with severe alopecia areata (hair loss) to see how the drug baricitinib changes certain immune markers in the blood. Researchers measured levels of two proteins, interleukin-15 and interferon gamma, before and after six months of treatment. The goal…
Matched conditions: ALOPECIA AREATA
Phase: NA • Sponsor: Benha University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Hair loss gene link explored in new study
Knowledge-focused CompletedThis study examined whether a specific change in the TLR7 gene is more common in people with alopecia areata, an autoimmune condition that causes hair loss. Researchers compared 120 participants (patients and healthy volunteers) to see if the gene variant is linked to the disease…
Matched conditions: ALOPECIA AREATA
Sponsor: Benha University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Scientists test designer immune molecules in autoimmune diseases
Knowledge-focused CompletedThis study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…
Matched conditions: ALOPECIA AREATA
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC